IL160231A0 - Adenosine a3 receptor agonists - Google Patents
Adenosine a3 receptor agonistsInfo
- Publication number
- IL160231A0 IL160231A0 IL16023102A IL16023102A IL160231A0 IL 160231 A0 IL160231 A0 IL 160231A0 IL 16023102 A IL16023102 A IL 16023102A IL 16023102 A IL16023102 A IL 16023102A IL 160231 A0 IL160231 A0 IL 160231A0
- Authority
- IL
- Israel
- Prior art keywords
- receptor agonists
- adenosine
- neutropennia
- leukopenia
- useful
- Prior art date
Links
- 239000002593 adenosine A3 receptor agonist Substances 0.000 title 1
- 101150046889 ADORA3 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000002364 leukopenia Diseases 0.000 abstract 1
- 231100001022 leukopenia Toxicity 0.000 abstract 1
- 208000031225 myocardial ischemia Diseases 0.000 abstract 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31106901P | 2001-08-08 | 2001-08-08 | |
| PCT/US2002/024696 WO2003014137A1 (en) | 2001-08-08 | 2002-08-06 | Adenosine a3 receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL160231A0 true IL160231A0 (en) | 2004-07-25 |
Family
ID=23205248
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16023102A IL160231A0 (en) | 2001-08-08 | 2002-08-06 | Adenosine a3 receptor agonists |
| IL160231A IL160231A (en) | 2001-08-08 | 2004-02-05 | Adenosine a3 receptor agonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL160231A IL160231A (en) | 2001-08-08 | 2004-02-05 | Adenosine a3 receptor agonists |
Country Status (20)
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| EP2048142A3 (en) * | 2001-04-26 | 2009-04-22 | Eisai R&D Management Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
| AU2002362443B2 (en) | 2001-10-01 | 2008-05-15 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having A2A agonist activity and compositions thereof |
| US6914053B2 (en) * | 2002-09-09 | 2005-07-05 | Cv Therapeutics, Inc. | Adenosine A3 receptor agonists |
| WO2004086034A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a3(adora3) |
| EP2256106B1 (en) | 2003-07-22 | 2015-05-06 | Astex Therapeutics Limited | 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| NZ585697A (en) | 2004-08-02 | 2011-12-22 | Univ Virginia Patent Found | 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity |
| CN101083998A (zh) * | 2004-11-22 | 2007-12-05 | 王者制药研究发展有限公司 | 用腺苷a3受体激动剂强化治疗hif-1介导的病症 |
| EP1845973B1 (en) | 2005-01-21 | 2015-08-12 | Astex Therapeutics Limited | Pharmaceutical compounds |
| GB0505219D0 (en) * | 2005-03-14 | 2005-04-20 | Novartis Ag | Organic compounds |
| US7381714B2 (en) * | 2005-05-19 | 2008-06-03 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| US7514417B2 (en) | 2005-05-19 | 2009-04-07 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| US7488720B2 (en) | 2005-10-13 | 2009-02-10 | Cv Therapeutics, Inc. | A1 adenosine receptor agonists |
| WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| US7589076B2 (en) * | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| DE102007012645A1 (de) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Substituierte Imidazo- und Triazolopyrimidine |
| JP5703432B2 (ja) * | 2007-03-28 | 2015-04-22 | ノイロサーチ アクティーゼルスカブ | プリニル誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用 |
| EP2142546B1 (en) | 2007-03-28 | 2017-06-07 | Saniona A/S | Purinyl derivatives and their use as potassium channel modulators |
| US20090088403A1 (en) * | 2007-05-07 | 2009-04-02 | Randy Blakely | A3 adenosine receptors as targets for the modulation of central serotonergic signaling |
| JP2011500716A (ja) * | 2007-10-16 | 2011-01-06 | ギリアード・パロ・アルト・インコーポレイテッド | A3アデノシン受容体アンタゴニスト |
| US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| RU2451010C1 (ru) * | 2011-01-11 | 2012-05-20 | Закрытое Акционерное Общество "Ива Фарм" | Палладиево-медные катализаторы гомогенного селективного окисления тиольных групп, комбинация и композиция на их основе и способ терапевтического воздействия |
| EP2885290B1 (en) | 2012-06-26 | 2017-10-18 | Saniona A/S | A phenyl triazole derivative and its use for modulating the gabaa receptor complex |
| WO2014138485A1 (en) * | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| CN120647702A (zh) * | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
| ES3070946T3 (en) | 2019-03-12 | 2026-06-18 | Arcus Biosciences Inc | Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation |
| CA3135487A1 (en) | 2019-03-29 | 2020-10-08 | Arcus Biosciences, Inc. | Treatment of cancer utilizing an identified adenosine fingerprint |
| US20220332750A1 (en) * | 2019-06-21 | 2022-10-20 | Academy Of Military Medical Sciences | Adenosine compound, its pharmaceutically acceptable salt or its stereoisomer and use thereof |
| JP2024502068A (ja) * | 2020-12-29 | 2024-01-17 | チョーチヤン ビムグリーン ファーマシューティカルズ、リミテッド | A3アデノシン受容体アゴニスト及びその調製方法と用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
| US6180615B1 (en) * | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
| US6403567B1 (en) * | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
-
2002
- 2002-08-05 US US10/212,896 patent/US20030078232A1/en not_active Abandoned
- 2002-08-06 AU AU2002327426A patent/AU2002327426C1/en not_active Ceased
- 2002-08-06 ES ES02763415T patent/ES2247371T3/es not_active Expired - Lifetime
- 2002-08-06 KR KR1020047001949A patent/KR100923888B1/ko not_active Expired - Fee Related
- 2002-08-06 PL PL02368205A patent/PL368205A1/xx not_active Application Discontinuation
- 2002-08-06 DK DK02763415T patent/DK1414837T3/da active
- 2002-08-06 WO PCT/US2002/024696 patent/WO2003014137A1/en not_active Ceased
- 2002-08-06 HU HU0401437A patent/HUP0401437A3/hu unknown
- 2002-08-06 EP EP02763415A patent/EP1414837B1/en not_active Expired - Lifetime
- 2002-08-06 CA CA002456744A patent/CA2456744A1/en not_active Abandoned
- 2002-08-06 RU RU2004106635/04A patent/RU2298557C2/ru not_active IP Right Cessation
- 2002-08-06 DE DE60206775T patent/DE60206775T2/de not_active Expired - Lifetime
- 2002-08-06 CN CNB02815486XA patent/CN1244589C/zh not_active Expired - Fee Related
- 2002-08-06 MX MXPA04001185A patent/MXPA04001185A/es active IP Right Grant
- 2002-08-06 IL IL16023102A patent/IL160231A0/xx unknown
- 2002-08-06 AT AT02763415T patent/ATE307136T1/de not_active IP Right Cessation
- 2002-08-06 NZ NZ530976A patent/NZ530976A/en not_active IP Right Cessation
- 2002-08-06 JP JP2003519086A patent/JP4357960B2/ja not_active Expired - Fee Related
-
2004
- 2004-02-05 IL IL160231A patent/IL160231A/en not_active IP Right Cessation
- 2004-02-06 ZA ZA200401000A patent/ZA200401000B/en unknown
- 2004-03-05 NO NO20040969A patent/NO327997B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1414837A1 (en) | 2004-05-06 |
| AU2002327426C1 (en) | 2008-03-06 |
| KR100923888B1 (ko) | 2009-10-28 |
| HUP0401437A2 (hu) | 2004-11-29 |
| JP4357960B2 (ja) | 2009-11-04 |
| AU2002327426A2 (en) | 2003-02-24 |
| PL368205A1 (en) | 2005-03-21 |
| DE60206775D1 (de) | 2006-03-02 |
| RU2004106635A (ru) | 2005-07-27 |
| EP1414837B1 (en) | 2005-10-19 |
| RU2298557C2 (ru) | 2007-05-10 |
| ZA200401000B (en) | 2004-10-18 |
| NO20040969L (no) | 2004-04-19 |
| US20030078232A1 (en) | 2003-04-24 |
| IL160231A (en) | 2010-11-30 |
| CN1244589C (zh) | 2006-03-08 |
| NO327997B1 (no) | 2009-11-09 |
| DE60206775T2 (de) | 2006-07-20 |
| CN1538972A (zh) | 2004-10-20 |
| KR20040023733A (ko) | 2004-03-18 |
| HUP0401437A3 (en) | 2007-05-29 |
| WO2003014137A1 (en) | 2003-02-20 |
| NZ530976A (en) | 2005-07-29 |
| ES2247371T3 (es) | 2006-03-01 |
| DK1414837T3 (da) | 2005-11-07 |
| CA2456744A1 (en) | 2003-02-20 |
| AU2002327426B2 (en) | 2007-06-14 |
| ATE307136T1 (de) | 2005-11-15 |
| MXPA04001185A (es) | 2005-06-17 |
| JP2005501842A (ja) | 2005-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160231A (en) | Adenosine a3 receptor agonists | |
| MXPA04001524A (es) | 29-enoles de rapamicina. | |
| AP2002002458A0 (en) | Compounds for the treatment of ischemia. | |
| ZA200309521B (en) | Substituted 2-pyridine-cyclohexane-1,4-diamine derivatives. | |
| ATE293618T1 (de) | 4, 5, 6, 7-tetrahydroindazolderivate als antitumormittel | |
| NO20020684L (no) | 3(5)-aminopyrazolderivater, fremgangsmåtet for deres fremstilling og deres anvendelse som antitumormidler | |
| AU2003205077A1 (en) | Imaging agents and methods of imaging naaladase of psma | |
| PT1459751E (pt) | (s,s)-reboxetina para tratar as enxaquecas | |
| MXPA02001497A (es) | Derivados de 3-(5)-ureido-pirazol, procedimiento para su preparacion y sus uso como agentes antitumorales. | |
| DZ3168A1 (fr) | Dérivés de purine. | |
| DE60207241D1 (de) | 5-amino-5-phenyl-7-cyclobutyl-pyrrolo(2,3-d)pyrimidin-derivate | |
| PT1218378E (pt) | Derivados de terc-butil-(7-metil-imidazo-¬1,2-a|-piridin-3-il)-amina | |
| MXPA03006093A (es) | Derivados de n(fenilsulfonil)glicina y su uso terapeutico. | |
| SI1699795T1 (sl) | Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati | |
| MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
| AU2003297318A1 (en) | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. | |
| AU2002223084A1 (en) | Nitrogen substituted 1,2,4-triazolo(3,4-a)phthalazine derivatives for enhancing cognition | |
| WO2004022573A3 (en) | Adenosine a3 receptor agonists | |
| HK1043058A1 (zh) | 异环磷酰胺芥子类似物及其用途 | |
| ES2166045T3 (es) | Procedimiento para la preparacion de compuestos de 4,6-bis(ariloxi)pirimidina asimetricos. | |
| WO2003039484A3 (en) | Novel compositions and methods for cancer | |
| WO1999043285A3 (en) | Sulphonamide derivatives | |
| EP1613606A4 (en) | PROCESS FOR PREPARING 2,3,5,6-SUBSTITUTED 3H-PYRIMIDIN-4-ONES | |
| TR200103219T2 (tr) | Nöropatik ağrının iyileştirilmesinde kullanım için aroil aminoasil piroller | |
| ITBO980664A0 (it) | Composizione , procedimento e apparecchiatura per la lucidatura di pez zi . |